Healthcare >> Analyst Interviews >> August 18, 2003
KEN TRBOVICH is a Vice President in equity research for C.E. Unterberg,
Towbin. He has seven years' experience researching and analyzing US
public companies, including three years exclusively focused on coverage
of small-and mid-capitalization drug development and specialty
pharmaceutical companies. The latter includes coverage of late-stage
(Phase III clinical trials) biotechnology companies, firms developing
new formulations of existing products to protect brands from generic
substitution, and corporations attempting to expand the market for
currently approved products through clinical studies of new indications.
His education includes a BSBA in Accounting from the University of
Arizona and a Master's from Thunderbird (American Graduate School of
International Management). He is also a CFA charterholder. Profile
Mr. Trbovich: First off on the male side there have been a couple of
delays for long anticipated drugs. Those are Levitra
